Natural and acquired inhibitors of hemostasis in selected symptomatic outpatients with venous thromboembolic disease.
Mario Bazzan(Ospedale San Giovanni Bosco), Alessandro Pileri(Azienda USL di Bologna), C Rabbia, A Vaccarino(Istituto di Ematologia di Bologna), E Aluffi, Barbara Montaruli(A. O. Ordine Mauriziano di Torino), Alessandra Borchiellini, A. Pannocchia(Istituto di Ematologia di Bologna), G. Tamponi(Istituto di Ematologia di Bologna), Piercarla Schinco(Azienda Ospedaliero Universitaria San Giovanni Battista)
PubMed
October 6, 1997
Cited by 1
Related Papers
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
|New England Journal of Medicine|2001|599
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
|Journal of Clinical Oncology|2015|419
Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients
|Journal of Clinical Oncology|2005|305
Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas
|Journal of Clinical Oncology|2006|230